Showing 850 results
-
Media Release /East Hanover, March 28, 2023 — Updates to the NCCN Guidelines® for breast cancer, released in January 2023, recommend ribociclib (Kisqali®) as the only Category 1 preferred CDK4/6 inhibitor (…
-
Media Release /New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months…
-
Media Release /Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide,…
-
Media Release /- Decision could speed access to LCZ696 for heart failure with reduced ejection fraction patients in the US, reducing total review time from 12 to 8 months(1) - Filing is based on results from the…
-
Media Release /Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (…
-
Media Release /Funding and in-kind donations to support local initiatives and communities in the US impacted by the outbreak First grants to focus on immediate need for digital tools and frontline medical…
-
Media Release /- STEP (Solutions to Empower Patients)™ Program helps nonprofit organizations deliver innovative solutions to patient communities - Funded programs aim to improve the experience of people living…
-
Media Release /With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction(1) Leqvio provides effective and sustained…
